UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 271

Sortiert nach

1.12.2 ADVANCES IN CSF BIOMARKERS OF PARKINSON'S DISEASE

Parkinsonism & related disorders, 2012-01, Vol.18, p.S5-S6

LeWitt, P

2012

Link zum Volltext

Verfügbarkeit prüfen

Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases

Journal of the neurological sciences, 2003-03, Vol.207 (1), p.71-76

2003

Link zum Volltext

Verfügbarkeit prüfen

Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

Journal of neurochemistry, 1995-08, Vol.65 (2), p.710-716

1995

Link zum Volltext

Verfügbarkeit prüfen

2.244 Efficacy of rotigotine transdermal patch as adjunct to levodopa in subgroups of advanced-stage Parkinson's patients

Parkinsonism & related disorders, 2007, Vol.13, p.S110-S110

LeWitt, P

2007

Link zum Volltext

Verfügbarkeit prüfen

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

Neurology, 2007-04, Vol.68 (16), p.1262

2007

Link zum Volltext

Verfügbarkeit prüfen

Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders

Brain research, 1996-11, Vol.738 (2), p.265-274

1996

Link zum Volltext

Verfügbarkeit prüfen

Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience

Movement disorders, 1998-05, Vol.13 (3), p.377-382

1998

Link zum Volltext

Verfügbarkeit prüfen

CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease

Value in health, 2023-06, Vol.26 (6), p.S35-S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement

Movement disorders, 2014-12, Vol.29 (14), p.1710-1719

2014

Link zum Volltext

Verfügbarkeit prüfen

Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection

Movement disorders, 1997-11, Vol.12 (6), p.1064-1067

1997

Link zum Volltext

Verfügbarkeit prüfen

L‐DOPA Does Not Enhance Hydroxyl Radical Formation in the Nigrostriatal Dopamine System of Rats with a Unilateral 6‐Hydroxydopamine Lesion

Journal of neurochemistry, 2000-03, Vol.74 (3), p.1229-1240

2000

Link zum Volltext

Verfügbarkeit prüfen

P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring

Parkinsonism & related disorders, 2009, Vol.15, p.S63-S63

2009

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a Measurement Strategy for Parkinson's Disease: Assessing Patient Health-Related Quality of Life

Quality of life research, 2000-02, Vol.9 (1), p.87-100

2000

Link zum Volltext

Verfügbarkeit prüfen

Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations

Parkinsonism & related disorders, 2015-09, Vol.21 (9), p.1023-1030

2015

Link zum Volltext

Verfügbarkeit prüfen

2.247 Safe and tolerable switching from oral dopaminergic agonists to transdermal rotigotine in Parkinson's disease

Parkinsonism & related disorders, 2007, Vol.13, p.S110-S111

2007

Link zum Volltext

Verfügbarkeit prüfen

Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease

Movement disorders, 1998-07, Vol.13 (4), p.731-734

Lewitt, Peter A.

1998

Link zum Volltext

Verfügbarkeit prüfen

At last, a randomised controlled trial of apomorphine infusion

Lancet neurology, 2018-09, Vol.17 (9), p.732-733

LeWitt, Peter A

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa

Hypertension (Dallas, Tex. 1979), 2015-01, Vol.65 (1), p.101-107

2015

Link zum Volltext

Verfügbarkeit prüfen

Levodopa in the treatment of Parkinson's disease: a consensus meeting

Movement disorders, 1999-11, Vol.14 (6), p.911

1999

Link zum Volltext

Verfügbarkeit prüfen

Neuroprotection for Parkinson’s disease

Journal of neural transmission. Supplementum, 2006 (71), p.113-122

LeWitt, P. A.

2006

Link zum Volltext

Verfügbarkeit prüfen

P2.147 Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients

Parkinsonism & related disorders, 2009, Vol.15, p.S129-S129

2009

Link zum Volltext

Verfügbarkeit prüfen

Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment

Movement disorders, 2005-06, Vol.20 (6), p.726-733

2005

Link zum Volltext

Verfügbarkeit prüfen

Levodopa in the treatment of Parkinson's disease: Current controversies

Movement disorders, 2004-09, Vol.19 (9), p.997-1005

2004

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Lancet neurology, 2019-02, Vol.18 (2), p.145-154

2019

Link zum Volltext

Verfügbarkeit prüfen

Continuous subcutaneous levodopa/carbidopa infusion (ND0612) for patients with Parkinson’s disease and motor fluctuations: A Phase 3, active-controlled study (BouNDless)

Parkinsonism & related disorders, 2024-05, Vol.122, p.106149, Article 106149

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(198)

Publikationsform

Sprache

Englisch
(270)
Japanisch
(32)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(197)
Life Sciences & Biomedicine
(193)
Humans
(179)
Neurosciences & Neurology
(142)
Biological And Medical Sciences
(121)
Clinical Neurology
(116)
Male
(114)
Medical Sciences
(109)
Middle Aged
(105)
Female
(97)
Aged
(83)
Parkinson Disease - Drug Therapy
(74)
Neurology
(72)
Adult
(65)
Pharmacology. Drug Treatments
(56)
Parkinson's Disease
(53)
Neurosciences
(47)
Neuropharmacology
(45)
Double-Blind Method
(39)
Anticonvulsants. Antiepileptics. Antiparkinson Agents
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

1.12.2 ADVANCES IN CSF BIOMARKERS OF PARKINSON'S DISEASE

Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases

Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

2.244 Efficacy of rotigotine transdermal patch as adjunct to levodopa in subgroups of advanced-stage Parkinson's patients

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders

Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience

CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease

Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement

Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection

L‐DOPA Does Not Enhance Hydroxyl Radical Formation in the Nigrostriatal Dopamine System of Rats with a Unilateral 6‐Hydroxydopamine Lesion

P1.135 Automated Parkinson's disease motor assessment for clinical and ambulatory monitoring

Evaluation of a Measurement Strategy for Parkinson's Disease: Assessing Patient Health-Related Quality of Life

Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations

2.247 Safe and tolerable switching from oral dopaminergic agonists to transdermal rotigotine in Parkinson's disease

Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease

At last, a randomised controlled trial of apomorphine infusion

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa

Levodopa in the treatment of Parkinson's disease: a consensus meeting

Neuroprotection for Parkinson’s disease

P2.147 Treatment of patients with early and advanced Parkinson's disease with transdermal rotigotine: safety and tolerability in elderly patients

Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment

Levodopa in the treatment of Parkinson's disease: Current controversies

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

Continuous subcutaneous levodopa/carbidopa infusion (ND0612) for patients with Parkinson’s disease and motor fluctuations: A Phase 3, active-controlled study (BouNDless)

Suchergebnisse filtern